Back to Awarded Treatment Trials
Awarded Trial: 01-074
Grant ID
01-074
Illness
Schizophrenia
Primary Drug/Intervention
Risperidone Added to Clozapine
Primary Dosage
2-6mg/day
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Anil
Sample Size
30
Duration of Study Period for Each Subject
6 weeks
Outcome Measurements
PANSS, CGI-S, CDS, GAF, QLS
Results
30 patients with schizophrenia who had partial response to clozapine received either placebo or risperidone augmentation in a six week double-blind, randomized, design. Both groups improved on a variety of measures of psychopathology but there was significantly greater improvement in placebo treated patients on the PANSS positive subscale. In evaluating the results it may be noteworthy that duration of illness, clozapine dose and number of previous hospitaizations were higher in the group that received risperidone.
Publication
Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry. 2005 Jan;66(1):63-72. Kivircik Akdede BB, Anil Yagcioglu AE, Alptekin K et al. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. J Clin Psychiatry. 2006 Dec;67(12):1912-9.
Link
http://www.ncbi.nlm.nih.gov/pubmed/15669890; http://www.ncbi.nlm.nih.gov/pubmed/17194269
PI Name
Elif Anil
Degree
MD
Center
Department of Psychiatry
Institution
Hacettepe University, Faculty of Medicine
Address
Sihhiye
City or Town
Ankara
State or Province
N/A
Zip or Postal Code
6100
Country
Turkey
Email Address
eanil@hacettepe.edu.tr